Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer Market Outlook Report 2032 | Pfizer, Novartis, AstraZeneca Pharmaceuticals, Eli Lilly, Jiangsu HengRui Medicine, Odonate Therapeutics, Radius Pharmaceuticals, Immunom

DelveInsight's "Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer, historical and forecasted epidemiology as well as the Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.


The Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer market size from 2019 to 2032, segmented by seven major markets. The Report also covers current Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer market.

Request for a Free Sample Report @ https://www.delveinsight.com/sample-request/hr-positive-her2-negative-breast-cancer-market-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer Overview

Hormone receptor (HR) positive/human epidermal receptor 2 (HER2) negative breast cancer is a subtype of breast cancer characterized by the presence of receptors for estrogen (ER) and/or progesterone (PR) on the surface of the cancer cells, and the absence of overexpression or amplification of the HER2 protein. This subtype tends to grow more slowly and is typically more responsive to hormonal therapy compared to other breast cancer types.
Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer Causes
The exact cause of HR-positive/HER2-negative breast cancer is not fully understood, but several risk factors have been identified:
Genetic Factors:
Family history of breast cancer.
Genetic mutations (e.g., BRCA1 and BRCA2, though these are less common in HR-positive cases).
Hormonal Factors:
Prolonged exposure to estrogen, such as early menarche or late menopause.
Hormone replacement therapy (HRT) during menopause.
Lifestyle Factors:
Alcohol consumption.
Obesity, particularly after menopause.
Lack of physical activity.
Reproductive History:
Nulliparity (never having given birth) or late age at first childbirth.
Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer Signs and Symptoms
Symptoms of HR-positive/HER2-negative breast cancer are similar to other breast cancer types and can include:
Breast Lump: A new lump or mass in the breast, often painless.
Changes in Breast Shape or Size: Noticeable alterations in the appearance of the breast.
Skin Changes: Dimpling, puckering, or redness of the skin on the breast.
Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer Diagnosis
Diagnosis involves several steps to confirm the presence of cancer and determine its specific characteristics:
Physical Examination:
Clinical breast exam to check for lumps or other changes.
Imaging Studies:
Mammography: X-ray of the breast to identify abnormal areas.
Ultrasound: Helps distinguish between solid masses and fluid-filled cysts.
MRI: Provides detailed images, especially useful in dense breast tissue.
Biopsy:
Fine-Needle Aspiration (FNA): Uses a thin needle to extract cells from a lump.
Core Needle Biopsy: Uses a larger needle to remove a core of tissue.
Surgical Biopsy: Involves removing a part or all of a lump for examination.
Pathology Report:
Hormone Receptor Testing: Determines if cancer cells have receptors for estrogen and progesterone.
HER2 Testing: Assesses the level of HER2 protein or gene amplification.
Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer Treatment Options
Treatment for HR-positive/HER2-negative breast cancer involves a multimodal approach, which can include:
Surgery:
Lumpectomy: Removal of the tumor and a small margin of surrounding tissue.
Mastectomy: Removal of the entire breast.
Sentinel Lymph Node Biopsy: Identifies if cancer has spread to lymph nodes.
Axillary Lymph Node Dissection: Removal of more lymph nodes if cancer is found.
Radiation Therapy:
Often follows lumpectomy to destroy any remaining cancer cells in the breast area.
May also be used after mastectomy in certain high-risk cases.
Hormonal (Endocrine) Therapy:
Tamoxifen: Blocks estrogen receptors, commonly used in premenopausal women.
Aromatase Inhibitors (e.g., Anastrozole, Letrozole): Lower estrogen levels, mainly used in postmenopausal women.
Ovarian Suppression: Medications or surgery to stop the ovaries from producing estrogen in premenopausal women.
Chemotherapy:
Used in higher-risk cases or when hormonal therapy alone is insufficient.
Often recommended based on tumor size, grade, and lymph node involvement.
Targeted Therapy:
While not specific to HR-positive/HER2-negative subtype, certain cases may benefit from newer targeted agents, depending on genetic testing and tumor characteristics.
Bone-Modifying Agents:
Bisphosphonates or Denosumab: Used to strengthen bones and reduce the risk of metastasis in postmenopausal women.
Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer Follow-up and Monitoring
Regular follow-up is crucial for monitoring treatment response and early detection of recurrence. This typically involves:
Physical Exams: Every 3-6 months for the first few years, then annually.
Mammograms: Annually, or as recommended by the healthcare provider.
Bone Density Tests: For those on aromatase inhibitors, to monitor bone health.
HR-positive/HER2-negative breast cancer generally has a favorable prognosis, particularly when detected early and treated appropriately. Ongoing research continues to improve the understanding and management of this breast cancer subtype, offering hope for even better outcomes in the future.
Learn more about Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer, treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ https://www.delveinsight.com/report-store/hr-positive-her2-negative-breast-cancer-market-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer Market

The Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer market trends by analyzing the impact of current Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer therapies on the market and unmet needs, drivers, barriers, and demand for better technology.

This segment gives a thorough detail of the Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer market in 7MM is expected to witness a major change in the study period 2019-2032.

Request a sample and discover more about the report offerings at:
https://www.delveinsight.com/sample-request/hr-positive-her2-negative-breast-cancer-market-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer Epidemiology

The Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer epidemiology section provides insights into the historical and current Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer market report also provides the diagnosed patient pool, trends, and assumptions.

Explore more about Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer Epidemiology at: https://www.delveinsight.com/report-store/hr-positive-her2-negative-breast-cancer-market-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer Drugs Uptake

This section focuses on the uptake rate of the potential Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer drugs recently launched in the Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer market or expected to be launched in 2019-2032. The analysis covers the Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug.

Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer Pipeline Development Activities

The Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer report provides insights into different therapeutic candidates in Phase II and Phase III stages. It also analyses Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer key players involved in developing targeted therapeutics.

Request for a sample copy of the report to understand more about the Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer pipeline development activities at: https://www.delveinsight.com/report-store/hr-positive-her2-negative-breast-cancer-market-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer Therapeutics Assessment

Prominent players such as Pfizer, Novartis, AstraZeneca Pharmaceuticals, Eli Lilly, Jiangsu HengRui Medicine, Odonate Therapeutics, Radius Pharmaceuticals, Immunomedics, and others are working proactively in the Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer Therapeutics market to develop novel therapies which will drive the Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer treatment markets in the upcoming years.

Learn more about the emerging therapies & key companies at: https://www.delveinsight.com/report-store/hr-positive-her2-negative-breast-cancer-market-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer Report Key Insights

1. Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer Patient Population
2. Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer Market Size and Trends
3. Key Cross Competition in the Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer Market
4. Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer Market Dynamics (Key Drivers and Barriers)
5. Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer Market Opportunities
6. Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer Therapeutic Approaches
7. Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer Pipeline Analysis
8. Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer Current Treatment Practices/Algorithm
9. Impact of Emerging Therapies on the Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer Market

Table of Contents

1. Key Insights
2. Executive Summary
3. Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer Competitive Intelligence Analysis
4. Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer Market Overview at a Glance
5. Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer Disease Background and Overview
6. Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer Patient Journey
7. Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer Epidemiology and Patient Population
8. Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer Treatment Algorithm, Current Treatment, and Medical Practices
9. Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer Unmet Needs
10. Key Endpoints of Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer Treatment
11. Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer Marketed Products
12. Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer Emerging Therapies
13. Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer Seven Major Market Analysis
14. Attribute Analysis
15. Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer Market Outlook (7 major markets)
16. Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer Access and Reimbursement Overview
17. KOL Views on the Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer Market
18. Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer Market Drivers
19. Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer

Get the Detailed TOC of the Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer Market report here: https://www.delveinsight.com/report-store/hr-positive-her2-negative-breast-cancer-market-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Us:

Kritika Rehani
info@delveinsight.com
+91-9650213330
www.delveinsight.com

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.